Anti-LRP (Multidrug resistance-related antigen), Clone LMR5
产品名称: Anti-LRP (Multidrug resistance-related antigen), Clone LMR5
英文名称: Anti-LRP (Multidrug resistance-related antigen), Clone LMR5
产品编号: MC-601
产品价格: null
产品产地: USA
品牌商标: KAMIYA
更新时间: 2024-12-10T13:14:19
使用范围:
- 联系人 : 李自转
- 地址 : 上海市浦东新区天雄路166弄一号楼三层南单元
- 邮编 : 200030
- 所在区域 : 上海
- 电话 : 139****5640 点击查看
- 传真 : 点击查看
- 邮箱 : lizizhuan@yeasen.com
- 二维码 : 点击查看
Product: Anti-LRP (Multidrug resistance-related antigen), Clone LMR5
Cat. No: MC-601 (1 ml)
MC-600 (0.5 ml)
Specificity:
Monoclonal antibody recognizes the 110 kDa
Lung Resistance Protein (LRP). Reacts with an
internal epitope of the LRP-protein (p110). LRP,
also known as the Major Vault Protein, is
upregulated and strongly overexpressed in
various human P-glycoprotein negative MDR
tumor cells.
Ig Isotype: Rat IgG
Immunogen:
110 kDa LRP-protein (p110).
Hybridoma:
Mouse myeloma (SP2/O) x immunized mouse
(outbred Wistar) lymph node cells
Format:
1 ml (>200 tests) containing ~50 μg IgG in
serum-free culture supernatant with 1 BSA
and 0.1 NaN3. Filtered through a 0.22 μm filter.
Storage and Stability:
Stable for at least 2 months when stored at 2-
8°C, and 1 year at -20°C. Avoid repeated
freeze/thaw cycles.
Applications and Suggested Dilutions:
Can be used for the detection of LRP-associated
non-Pglycoprotein MDR in human tumor
samples.
Flow Cytometry: Use at lease a 1:50 dilution
after fixing cells in 10 (v/v) Lysing solution G
(Becton-Dickinson) in H2O, followed by
incubation with anti-mouse-FITC.
Immunohistochemistry: (Acetone-fixed frozen
sections or cytospin preparations)- Use at
least a 1:20-1:50 dilution. (Formalin-fixed,
paraffin-embedded tissue)- Use a 1:20
dilution.
The optimal dilution for a specific application
should be determined by the researcher.
References:
1. Scheper, R.J. et al. (1993). Overexpression
of a Mr 110,000 vesicular protein in non-Pglycoprotein-
mediated multidrug resistance.
Cancer Res. 53:1475-79.
2. Izquierdo, M.A. et al. (1995). Drug
resistance-associated marker Lrp for
prediction of response to chemotherapy and
prognoses in advanced ovarian cancer. J.
Natl. Cancer Inst. 87: 1230-37.
3. Scheffer, G. et al. (1995). The drugresistance-
related protein LRP is the human
major vault protein. Nature Med. 1(6): 578-
82.
4. Moran, E. et al. (1997). Co-expression of
MDR-associated markers, including P-170,
MRP and LRP and cytoskeletal proteins, in
three resistant variants of the human ovarian
carcinoma cell line, OAW42. Eur. J. Cancer
33: 652-60.
Limitations:
For in vitro research use only. Not for use in
diagnostics or in humans.
Warranty:
No warranties, expressed or implied, are made
regarding the use of this product. KAMIYA
BIOMEDICAL COMPANY is not liable for any
damage, personal injury, or economic loss
caused by this product.